One in five adults said they experienced any symptoms of anxiety or depression in a 2-week period, according to a 2022 CDC ...

"This data gives patients the option to benefit from esketamine treatment either with or without an antidepressant," said ...

recently approved esketamine for treatment-resistant depression. However, its rapid and efficacious antidepressant activity is offset by the significant rate of psychotomimetic and dissociative ...

More information: Jennifer Kern Sliwa et al, Effects of esketamine nasal spray on depressive symptom severity in adults with ...

Brain and Cognition Discovery Foundation, Toronto, ON, Canada Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada Department of Pharmacology & Toxicology, University ...

Johnson & Johnson is to press on with filings for its new depression drug, esketamine, despite one of two late-stage studies missing an efficacy target. Ketamine is best known as an anaesthetic ...

Esketamine, the S isomer of ketamine, has already gained approval for treatment-resistant depression under the trademark Spravato; psilocybin and ketamine have been shown to provide benefits to ...

Initial studies demonstrating rapid antidepressant effects drove research leading to the recent US Food and Drug Administration (FDA) approval of intranasal esketamine, the first (and at present, only ...

Mental health is a vital aspect of overall well-being, especially for students who face unique pressures and challenges. From ...

The US drugs regulator has approved the sale of a new nasal spray to treat depression. Manufacturer Janssen says Esketamine can lift a patient's mood within 24 hours of use. The drug is intended ...

(The Guardian) Greater depression severity was significantly ... A previous version of the story stated esketamine's label warning was new. The existing warning was updated.

Janssen’s potential depression treatment made from esketamine – a version of the substance notoriously used illegally as a party drug – is to be reviewed by advisers to the FDA at a crunch ...